Skip to content
What Causes What
MECHANISM− DECREASES

GLP-1 receptor agonist → Alcohol intake

Higher GLP-1 receptor agonist decreases Alcohol intake.

In 108 people seeking treatment for alcohol use disorder and obesity, weekly semaglutide 2.4 mg plus usual therapy cut heavy-drinking days by about 14 percentage points versus placebo plus the same therapy (Klausen 2026). An earlier exenatide trial missed that same primary end point.

Randomized trial · Contested · N=108

Supported by an experiment or a tightly identified design. Read the caveats.

Mechanism

GLP-1 receptors sit in gut and in reward circuits. The drugs slow the stomach and blunt cue-driven wanting. Authors treat that as a path from an incretin pen to fewer drinks, not only to a smaller waist. Klausen, Justesen, Pedersen and colleagues (2026) assigned 108 treatment-seeking adults with moderate-to-severe alcohol use disorder and obesity to weekly semaglutide 2.4 mg or saline, both with cognitive behavioural therapy, for 26 weeks. Heavy-drinking days fell 41.1 percentage points on drug versus 26.4 on placebo. Treatment difference -13.7 points (95 percent CI -22.0 to -5.4). abstract_only. Hendershot, Bremmer, Paladino and colleagues (2025) assigned 48 non-treatment-seeking adults with alcohol use disorder to weekly semaglutide, titrated to 1.0 mg, or placebo for 9 weeks. Grams drunk in a laboratory task fell (beta -0.48). Drinks per drinking day fell. Drinks per calendar day did not. full_text. Klausen 2022 assigned 127 treatment-seeking patients to weekly exenatide 2 mg or placebo for 26 weeks. Heavy-drinking days did not fall in the full sample. Cue reactivity in the ventral striatum did. An obese subgroup drank less. full_text.

Caveats

Someone was assigned a pen, so the stamp is an RCT stamp. The file is mixed, so confidence stays contested. Paper count does not raise it. The 2026 Lancet trial is one centre, 108 people, obesity required, and both arms got therapy. Eighty-one percent finished. Hendershot is 48 people, 9 weeks, and not a treatment-seeking sample. Calendar-day drinks did not move. Exenatide missed the primary end point in the full sample. A later oral semaglutide trial (Schacht 2026, N=50) missed laboratory craving and still cut heavy-drinking days. Dulaglutide cut drinks as a secondary look inside a smoking-cessation trial, not an alcohol-use-disorder trial. Did not hang the electronic-record association or the Reddit self-report file. Did not hang the narrative review. This page is a journal entry. It is not medical advice and not a reason to start or stop a drug.

Effect

qualitative. Klausen 2026 HDD ETD -13.7 pp (CI -22.0 to -5.4), N=108 AUD+obesity. Hendershot 2025 lab grams β -0.48, N=48. Exenatide 2022 primary HDD null.

Nodes

Lifestyle & environmentGLP-1 receptor agonistLifestyle & environmentAlcohol intake

Named confounders

Cite this page

What Causes What. “GLP-1 receptor agonist → Alcohol intake.” https://whatcauseswhat.org/edges/e-glp1-alcohol (atlas updated 2026-09-02).

https://whatcauseswhat.org/edges/e-glp1-alcohol

Papers